Antibiotic resistance in the intensive care unit

Current Opinion in Critical Care

Volumn 8, Issue 5, 2002, Pages 430-434

  Baughman, Robert P ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MACROLIDE; METICILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; EPIDEMIC; HOSPITAL PERSONNEL; HUMAN; INTENSIVE CARE UNIT; REVIEW;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS;

EID: 0036792201     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200210000-00010     Document Type: Review

References (44)

1. Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit. Ann Intern Med 2001, 134:298-314.
2. Kollef MH, Sherman G, Ward S, et al.: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
3. Luna CM, Vujacich P, Niederman MS, et al.: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685.
4. Zaidi M, Sifuentes-Osornio J, Rolon AL, et al.: Inadequate therapy and antibiotic resistance. Risk factors for mortality in the intensive care unit. Arch Med Res 2002, 33:290-294.
5. Fridkin SK, Edwards JR, Tenover FC, et al.: Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001, 33:324-330.
6. Cosgrove SE, Kaye KS, Eliopoulous GM, et al.: Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162:185-190.
7. Carmeli Y, Troillet N, Karchmer AW, et al.: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999, 159:1127-1132.
8. Linden PK, Pasquulle AW, Manez R, et al.: Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996, 22:663-670.
9. Fierobe L, Lucet JC, Decre D, et al.: An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 2001, 22:35-40.
10. Dubois V, Arpin C, Melon M, et al.: Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol 2001, 39:2072-2078.
11. Miranda G, Leanos B, Marquez L, et al.: Molecular epidemiology of a multiresistant Pseudomonas aeruginosa outbreak in a pediatric intensive care unit. Scand J Infect Dis 2001, 33:738-743.
12. Grundmann H, Hori S, Winter B, et al.: Risk factors for the transmission of methicillin-resistant Staphylococcus aureus in an adult intensive care unit: fitting a model to the data. J Infect Dis 2002, 185:481-488.
13. Andersen BM, Lindemann R, Bergh K, et al.: Spread of methicillin-resistant Staphylococcus aureus in a neonatal intensive unit associated with understaffing, overcrowding and mixing of patients. J Hosp Infect 2002, 50:18-24.
14. Pelupessy I, Bonten MJ, Diekmann O: How to assess the relative importance of different colonization routes of pathogens within hospital settings. Proc Natl Acad Sci U S A 2002, 99:5601-5605.
15. Auburtin M, Porcher R, Bruneel F, et al.: Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med 2002, 165:713-717.
16. Moroney JF, Fiore AE, Harrison LH, et al.: Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001, 33:797-805.
17. Feikin DR, Schuchat A, Kolczak M, et al.: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000, 90:223-229.
18. Hendrix CW, Hammond JM, Swoboda SM, et al.: Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients. Ann Surg 2001, 233:259-265.
19. Moellering RC Jr, Linden PK, Reinhardt J, et al.: The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999, 44:251-261.
20. Diekema DJ, Jones RN: Oxazolidinone antibiotics. Lancet 2001, 358:1975-1982.
21. Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002, 346:867-869.
22. Gonzales RD, Schreckenberger PC, Graham MB, et al.: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357:1179.
23. Scanvic-Hameg A, Chachaty E, Rey J, et al.: Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers. J Antimicrob Chemother 2002, 49:135-139.
24. Fridkin SK, Edwards JR, Courval JM, et al.: The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001, 135:175-183.
25. Uehara Y, Kikuchi K, Nakamura T, et al.: Inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns by viridans group streptococci. Clin Infect Dis 2001, 32:1399-1407.
26. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997, 46:765-766.
27. Hiramatsu K, Aritaka N, Hanaki H, et al.: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673.
28. Diekema DJ, Pfaller MA, Schmitz FJ, et al.: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(suppl 2):S114-S132.
29. Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001, 7:327-332.
30. Werner G, Cuny C, Schmitz FJ, et al.: Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001, 39:3586-3590.
31. Tsiodras S, Gold HS, Sakoulas G, et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.
32. Ibrahim EH, Ward S, Sherman G, et al.: A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000, 117:1434-1442.
33. Trouillet JL, Vuagnat A, Combes A, et al.: Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002, 34:1047-1054.
34. Luzzaro F, Mantengoli E, Perilli M, et al.: Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. J Clin Microbiol 2001, 39:1865-1870.
35. Agusti C, Pujol M, Argerich MJ, et al.: Short-term effect of the application of selective decontamination of the digestive tract on different body site reservoir ICU patients colonized by multi-resistant Acinetobacter baumannii. J Antimicrob Chemother 2002, 49:205-208.
36. Petros AJ, O'Connell M, Roberts C, et al.: Systemic antibiotics fail to clear multidrug-resistant Klebsiella from a pediatric ICU. Chest 2001, 119:862-866.
37. Solomon DH, Van Houten L, Glynn RJ, et al.: Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med 2001, 161:1897-1902.
38. Kollef MH, Vlasnik J, Sharpless L, et al.: Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:1040-1048.
39. Niederman MS: Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med 1997, 156:1029-1031.
40. Puzniak LA, Mayfield J, Leet T, et al.: Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis 2001, 33:151-157.
41. Bradley SJ, Wilson AL, Allen MC, et al.: The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a hematology unit by changing antibiotic usage. J Antimicrob Chemother 1999, 43:261-266.
42. May AK, Melton SM, McGwin G, et al.: Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000, 14:259-264.
43. Singh N, Rogers P, Atwood CW, et al.: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
44. Ibrahim EH, Ward S, Sherman G, et al.: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29:1109-1115.